The first complete measurement of the $β$-decay strength distribution of $_{17}^{45}$Cl28 was performed at the Facility for Rare Isotope Beams (FRIB) with the FRIB Decay Station Initiator during the ...second FRIB experiment. The measurement involved the detection of neutrons and $γ$ rays in two focal planes of the FRIB Decay Station Initiator in a single experiment for the first time. This enabled an analytical consistency in extracting the $β$-decay strength distribution over the large range of excitation energies, including neutron unbound states. Here, we observe a rapid increase in the $β$-decay strength distribution above the neutron separation energy in $_{18}^{45}$Ar27. This was interpreted to be caused by the transitioning of neutrons into protons excited across the Z = 20 shell gap. The SDPF-MU interaction with reduced shell gap best reproduced the data. The measurement demonstrates a new approach that is sensitive to the proton shell gap in neutron rich nuclei according to SDPF-MU calculations.
The first complete measurement of the β-decay strength distribution of _{17}^{45}Cl_{28} was performed at the Facility for Rare Isotope Beams (FRIB) with the FRIB Decay Station Initiator during the ...second FRIB experiment. The measurement involved the detection of neutrons and γ rays in two focal planes of the FRIB Decay Station Initiator in a single experiment for the first time. This enabled an analytical consistency in extracting the β-decay strength distribution over the large range of excitation energies, including neutron unbound states. We observe a rapid increase in the β-decay strength distribution above the neutron separation energy in _{18}^{45}Ar_{27}. This was interpreted to be caused by the transitioning of neutrons into protons excited across the Z=20 shell gap. The SDPF-MU interaction with reduced shell gap best reproduced the data. The measurement demonstrates a new approach that is sensitive to the proton shell gap in neutron rich nuclei according to SDPF-MU calculations.
New astronomical observations point to a nucleosynthesis picture that goes beyond what was accepted until recently. The intermediate "i" process was proposed as a plausible scenario to explain some ...of the unusual abundance patterns observed in metal-poor stars. The most important nuclear physics properties entering i-process calculations are the neutron-capture cross sections and they are almost exclusively not known experimentally. Here we provide the first experimental constraints on the ^{139}Ba(n,γ)^{140}Ba reaction rate, which is the dominant source of uncertainty for the production of lanthanum, a key indicator of i-process conditions. This is an important step towards identifying the exact astrophysical site of stars carrying the i-process signature.
Debating Design Dembski, William A; Ruse, Michael
07/2004
eBook
In this book, first published in 2004, William Dembski, Michael Ruse, and other prominent philosophers provide a comprehensive balanced overview of the debate concerning biological origins - a ...controversial dialectic since Darwin published The Origin of Species in 1859. Invariably, the source of controversy has been 'design'. Is the appearance of design in organisms (as exhibited in their functional complexity) the result of purely natural forces acting without prevision or teleology? Or, does the appearance of design signify genuine prevision and teleology, and, if so, is that design empirically detectable and thus open to scientific inquiry? Four main positions have emerged in response to these questions: Darwinism, self-organisation, theistic evolution, and intelligent design. The contributors to this volume define their respective positions in an accessible style, inviting readers to draw their own conclusions. Two introductory essays furnish a historical overview of the debate.
Intravenous iloprost, titrated from 0.5 up to 2.0 ng/kg/min has been shown in patients with PAOD III/IV to significantly improve healing of trophic lesions, relief of rest pain, and reduce the rate ...of major amputation or death at 6 months as compared to placebo. The effect is considered related to improvement of the microcirculation. The aim of the present trial was to identify an optimum dose regarding treatment response and tolerability, by studying 4 doses of 25, 50, 75 and 100 micrograms iloprost daily.
302 patients with PAOD IV were randomised via a double-blind fashion to one of the 4 doses. The primary endpoint was the responder rate at end of treatment. Responders were defined as patients with very good or good global efficacy, as judged by lesion healing and pain relief. Side effects were documented and a pre-defined benefit/risk index was calculated.
No dose-dependency of iloprost regarding primary or secondary endpoints was observed. The rate of responders ranged between 48.7-53.5%. Side effects, mainly related to vasodilation, increased dose-dependently (p < 0.001, chi 2-test), with a significant decrease of the benefit/risk index from 2.19 +/- 1.19 to 1.64 +/- 0.97 (p = 0.012, ANOVA). Responders had a better outcome at 6 months than non-responders (2.6 fold higher rate of major amputation or death; life table analysis).
It is concluded that iloprost should be titrated to the optimum rather than maximum tolerated dose, since a higher incidence of side effects not associated with an increased treatment response was observed at higher doses.
